How I treat mantle cell lymphoma.
作者信息
Straus David J
出版信息
J Oncol Pract. 2007 Sep;3(5):281-2. doi: 10.1200/JOP.0758501.
Abstract
摘要
相似文献
1
How I treat mantle cell lymphoma.
J Oncol Pract. 2007 Sep;3(5):281-2. doi: 10.1200/JOP.0758501.
2
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol. 2021 Sep;8(9):e648-e657. doi: 10.1016/S2352-3026(21)00195-2.
3
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
J Hematol Oncol. 2018 Jun 15;11(1):83. doi: 10.1186/s13045-018-0621-5.
4
Unmet needs in the treatment of mantle cell lymphoma.
Clin Adv Hematol Oncol. 2013 Nov;11(11 Suppl 18):1-19.
5
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7.
6
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.
7
Recurrent mantle cell lymphoma in the uterine cervix: a case report.
J Med Case Rep. 2020 Sep 2;14(1):138. doi: 10.1186/s13256-020-02487-6.
8
Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(7):773-787. doi: 10.1080/14737167.2023.2216458. Epub 2023 Jun 6.
9
Mantle cell lymphoma disguised as marginal zone lymphoma.
Arch Pathol Lab Med. 2005 Jul;129(7):929-32. doi: 10.5858/2005-129-929-MCLDAM.
10
Mantle cell lymphoma presenting as acute appendicitis.
Int J Surg Case Rep. 2015;6C:33-5. doi: 10.1016/j.ijscr.2014.10.068. Epub 2014 Nov 21.
引用本文的文献
1
Nasopharyngeal Mantle Cell Lymphoma: An Extremely Rare Entity.
Oman Med J. 2019 Jan;34(1):74-77. doi: 10.5001/omj.2019.13.
本文引用的文献
1
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
J Clin Oncol. 2006 Oct 20;24(30):4867-74. doi: 10.1200/JCO.2006.07.9665. Epub 2006 Sep 25.
2
Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1185-91. doi: 10.1016/j.ijrobp.2006.02.011. Epub 2006 May 6.
3
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
J Clin Oncol. 2005 Oct 1;23(28):7013-23. doi: 10.1200/JCO.2005.01.1825. Epub 2005 Sep 6.
4
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
J Clin Oncol. 2005 Aug 10;23(23):5347-56. doi: 10.1200/JCO.2005.13.466. Epub 2005 Jun 27.
5
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
J Clin Oncol. 2005 Mar 20;23(9):1984-92. doi: 10.1200/JCO.2005.08.133. Epub 2005 Jan 24.
6
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
Blood. 2004 Dec 1;104(12):3535-42. doi: 10.1182/blood-2004-06-2275. Epub 2004 Aug 10.
7
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood. 2004 Nov 15;104(10):3064-71. doi: 10.1182/blood-2004-04-1323. Epub 2004 Jul 29.
8
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.
Blood. 2004 Oct 15;104(8):2269-71. doi: 10.1182/blood-2004-03-1091. Epub 2004 May 27.
9
Limited-stage mantle-cell lymphoma.
Ann Oncol. 2003 Oct;14(10):1555-61. doi: 10.1093/annonc/mdg414.
10
Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.
Br J Haematol. 2003 Mar;120(5):793-800. doi: 10.1046/j.1365-2141.2003.04140.x.
Zotero 插件